Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study

References

• Multiple Sclerosis Coalition. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. MSC; 2016. Available at: http://ms-coalition.org/cms/images/stories//dmt_consensus_ms_coalition092016.pdf. May 12, 2017
   Google Scholar
• Menzin J, Caon C, Nichols C, et al. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm 2013;19:S24-S40
   PubMed Web of Science ®Google Scholar
• Kremer IE, Evers SM, Jongen PJ, et al. Identification and prioritization of important attributes of disease-modifying drugs in decision making among patients with multiple sclerosis: a nominal group technique and best-worst scaling. PLoS One 2016;11:e0164862
   PubMed Web of Science ®Google Scholar
• Fox RJ, Salter AR, Tyry T, et al. Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database. Int J MS Care 2013;15:194-201
   PubMedGoogle Scholar
• Nazareth T, Friedman HS, Navaratnam P, et al. Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review. BMC Neurol 2016;16:187
   PubMed Web of Science ®Google Scholar
• Bergvall N, Petrilla AA, Karkare SU, et al. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective U.S. claims database analysis. J Med Econ 2014;17:696-707
   PubMedGoogle Scholar
• Kalincik T, Spelman T, Trojano M, et al. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. PLoS One 2013;8:e63480
   PubMedGoogle Scholar
• Wicks P, Rasouliyan L, Katic B, et al. The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis. BMC Res Notes 2016;9:434
   PubMedGoogle Scholar
• Devonshire V, Feinstein A, Gillet A. Treatment adherence, persistence, and compliance at 96 weeks in M.S. patients using RebiSmart® for injection of interferon β-1a (P3.037). Neurology 2016;86(SupplP3.037)
   Web of Science ®Google Scholar
• Zhornitsky S, Greenfield J, Koch MW, et al. Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. PLoS One 2015;10:e0123824
   PubMed Web of Science ®Google Scholar
• Ipsos Healthcare. Multiple sclerosis: the evolving competitive landscape, the future challenges & the opportunities. Ipsos Healthcare; 2016. Available at: https://www.ipsos.com/sites/default/files/2017-03/IpsosHealthcare-MS-WhitePaper.pdf. Paris, France. August 16, 2017
   Google Scholar
• Stijacic Cenzer I, Fung KZ, Boscardin WJ, et al. Macro computing Charlson Comorbidity Index from C.M.S. claims data. Francisco, CA: University of California San Francisco2013. Available at: http://www.lexjansen.com/wuss/2013/119_Paper.pdf. May 12, 2017
   Google Scholar
• Bergvall N, Lahoz R, Nazareth T, et al. Persistence with fingolimod versus dimethyl fumarate in patients with multiple sclerosis: retrospective analysis of US open-source pharmacy data. Value Health 2014;17:A400-1
   PubMed Web of Science ®Google Scholar
• Halpern R, Agarwal S, Dembek C, et al. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Prefer Adherence 2011;5:73-84
   PubMed Web of Science ®Google Scholar
• Torkildsen O, Myhr KM, Bo L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol 2016;23(Suppl1):18-27
   Web of Science ®Google Scholar
• Miclea A, Leussink VI, Hartung HP, et al. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study. J Neurol 2016;263:1626-32
   PubMed Web of Science ®Google Scholar
• Ryerson LZ, Green R, Confident G, et al. Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis. Ther Adv Neurol Disord 2016;9:454-61
   PubMed Web of Science ®Google Scholar
• Fernandez O, Arroyo R, Martinez-Yelamos S, et al. Long-term adherence to IFN beta-1a treatment when using RebiSmart(R) device in patients with relapsing-remitting multiple sclerosis. PLoS One 2016;11:e0160313
   PubMed Web of Science ®Google Scholar
• Smith MY, Sabido-Espin M, Trochanov A, et al. Postmarketing safety profile of subcutaneous interferon beta-1a given 3 times weekly: a retrospective administrative claims analysis. J Manag Care Spec Pharm 2015;21:650-60
   PubMed Web of Science ®Google Scholar
• Patten SB, Metz LM. Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler 2001;7:243-8
   PubMed Web of Science ®Google Scholar
• Linker RA, Haghikia A. Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy. Ther Adv Chronic Dis 2016;7:198-207
   PubMed Web of Science ®Google Scholar
• Longbrake EE, Ramsbottom MJ, Cantoni C, et al. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Mult Scler 2016;22:1061-70
   PubMed Web of Science ®Google Scholar
• Ghadiri M, Rezk A, Li R, et al. Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis. Neurol Neuroimmunol Neuroinflamm 2017;4:e340
   PubMed Web of Science ®Google Scholar
• Gross CC, Schulte-Mecklenbeck A, Klinsing S, et al. Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol Neuroimmunol 2016;3:e183
   PubMed Web of Science ®Google Scholar
• Baharnoori M, Lyons J, Dastagir A, et al. Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate. Neurol-Neuroimmunol 2016;3:e274
   PubMed Web of Science ®Google Scholar
• I.M.S. Institute for Healthcare Informatics. Medicines use and spending shifts. A review of the use of medicines in the U.S. in 2014. IMS; 2015. Available at: http://www.imshealth.com/files/web/IMSH%20Institute/Reports/Medicines_Use_and_Spending_Shifts/Medicine-Spending-and-Growth_1995-2014.pdf. Parsipanny, NJ. May 12, 2017
   Google Scholar
• Fogarty E, Schmitz S, Tubridy N, et al. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis. Mult Scler Relat Disord 2016;9:23-30
   PubMed Web of Science ®Google Scholar
• Hersh CM, Love TE, Cohn S, et al. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. Mult Scler Relat Disord 2016;10:44-52
   PubMed Web of Science ®Google Scholar
• Roche J, McCarry Y, Mellors K. Enhanced patient support services improve patient persistence with multiple sclerosis treatment. Patient Prefer Adherence 2014;8:805-11
   PubMed Web of Science ®Google Scholar
• Syed M, Rog D, Parkes L, et al. Patient expectations and experiences of multiple sclerosis interferon beta-1a treatment: a longitudinal, observational study in routine U.K. clinical practice. Patient Prefer Adherence 2014;8:247-55
   PubMed Web of Science ®Google Scholar
• Hansen K, Schussel K, Kieble M, et al. Adherence to disease modifying drugs among patients with multiple sclerosis in Germany: a retrospective cohort study. PLoS One 2015;10:e0133279
   PubMed Web of Science ®Google Scholar
• Freedman MS. Efficacy and safety of subcutaneous interferon-beta-1a in patients with a first demyelinating event and early multiple sclerosis. Expert Opin Biol Ther 2014;14:1207-14
   PubMed Web of Science ®Google Scholar